www.fdanews.com/articles/203841-moderna-gains-fast-track-designation-for-mrna-based-rsv-vaccine
Moderna Gains Fast-Track Designation for mRNA-Based RSV Vaccine
August 5, 2021
The FDA has granted Moderna Fast-Track designation for mRNA-1345, its investigational single-dose mRNA vaccine against respiratory syncytial virus (RSV) in adults older than age 60.
Moderna’s RSV vaccine candidate uses the same lipid nanoparticle as the company’s authorized COVID-19 vaccine and contains optimized protein and nucleotide sequences.
There is currently no approved vaccine for RSV, a common respiratory virus that generally causes cold-like symptoms but can be fatal for elderly adults and young children.